Tocotrienol Supplementation Significantly Decreases Glycated Hemoglobin in Type 2 Diabetes Patients

Findings from the latest systematic review and meta-analysis of RCTs revealed for the first time that tocotrienol supplementation significantly reduced HbA1c level in individuals with diabetes.

A total of 10 studies were selected for the meta-analysis. Out of the 10 studies included in the meta-analysis, 9 used tocotrienol sourced from palm oil. Upon close examination, 8 of the studies were conducted using the same palm mixed-tocotrienol complex formulated with a bioenhanced delivery system.

In their review, the researchers focused on the effects of tocotrienol supplementation on HbA1c (a valuable indicator for blood sugar control), blood pressure and serum HsCRP (measurement of non-specific inflammation) levels.

Although reduction in HbA1c was found to be significant, there was a lack of effect in blood pressure and serum Hs-CRP reduction, which the researchers said was likely due to the fact that most of the studies analyzed involved individuals with longer duration of diabetes.

The researchers concluded in the study that short term tocotrienol supplementation (6 months) at high dosages (250 – 400mg) resulted in significant HbA1c reduction, especially in individuals having diabetes under 10 years.

“This latest publication showed that tocotrienol, a non-pharmaceutical agent, is a promising natural health ingredient for supporting glycemic control in diabetes. From the review, it is also remarkable that 8 of the 10 studies were conducted using the bioenhanced palm mixed-tocotrienol complex (contains EVNol™ from ExcelVite), whose effects on complications associated with long-term diabetes, namely, diabetic neuropathy, nephropathy and retinopathy, have been well studied.” – ExcelVite.

Reference:

Sonia C.W. Phang, Badariah Ahmad, Khalid Abdul Kadir, Uma Devi M Palanisamy,

Effects of Tocotrienol-Rich Fraction Supplementation in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials,

Advances in Nutrition, 2023, ISSN 2161-8313, 

Click here for related information.

Disclaimer: The statements in the above article have not been evaluated by the Food and Drug Administration. They are not intended to diagnose, treat, cure or prevent any disease.